Interstitial Cystitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Jan. 20, 2012 - PRLog -- GlobalData analysis shows that the global Interstitial Cystitis (IC) therapeutics market stood at $116.9m in 2006, and grew at a Compound Annual Growth Rate (CAGR) of 5.2% to reach $151m in 2011. GlobalData forecasts that the global IC therapeutics market will grow at a CAGR of 6.3% over the next eight years to reach $245.7m by 2019. The current approved treatment option for IC includes pentosan polysulphate sodium (Elmiron) and dimethyl sulfoxide (Rimso-50), both of which are now off patent. The generic dimethyl sulfoxide was launched in 2002; however, a generic pentosan polysulphate sodium is not yet available. Due to the limited availability of approved therapies, the current line of treatment is dominated by off-label drug options such as antidepressants (amitriptyline), antihistamines (hydroxyzine), analgesics (opioid and non-steroidal) and others. The IC therapeutics market is predicted to experience static growth during the forecast period, primarily due to the limited availability of approved products, low diagnosis rate, and lack of new product approvals during this period.

According to GlobalData analysis, the IC therapeutics market is weak at present. The market currently has only two approved treatment options for IC, namely Elmiron (pentosan polysulphate sodium) and Rimso-50 (dimethyl sulfoxide). Elmiron was approved on September 26, 1996, and its patent expired on
January 19, 2010. Similarly, Rimso-50 was approved prior to January 1, 1982, and its patent expired before 2002. Elmiron must be orally administered three times a day for at a long treatment regimen of least six months. Rimso-50 is instilled intravesically in the bladder for 15 minutes to reduce inflammation, which is a painful and inconvenient process. Other off-label options include amitriptyline, hydroxyzine, and analgesics. All these available treatment options provide symptomatic relief only, and do not target the underlying cause of disease. These products also have efficacy limitations for IC. Therefore, the IC therapeutics market is currently weak, due to limitations regarding the efficacy and compliance of available products.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData analysis suggests that the current pipeline for the IC therapeutics market is weak. The pipeline of IC treatment consists of 12 molecules, with one molecule in phase III, five molecules in phase II, and three molecules in phase I and the pre-clinical stage. There are seven First-In-Class (FIC) molecules, two me-too molecules, and two product extensions in the various stages of clinical development. Phase III of the pipeline does not have any company sponsored molecule. The only Phase
III molecule, Humira (adalimumab), is being studied by IC study and Abbott is the collaborator for the study. The rest of the molecules are in early stages of development, and their impact on the market is entirely dependent on their clinical trial results.

GlobalData, the industry analysis specialist, has released its new report, “Interstitial Cystitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis, identifying the key trends shaping and driving the global interstitial cystitis therapeutics market. The report also provides insights on the competitive landscape, emerging players expected to affect the market positioning of current market leaders, and pipeline products within the global interstitial cystitis therapeutics sector. This report has been built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Inte...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.